---
title: "600276.SH (600276.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600276.SH/news.md"
symbol: "600276.SH"
name: "600276.SH"
parent: "https://longbridge.com/en/quote/600276.SH.md"
datetime: "2026-05-19T16:11:13.398Z"
locales:
  - [en](https://longbridge.com/en/quote/600276.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600276.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600276.SH/news.md)
---

# 600276.SH (600276.SH) — Related News

### [Hengrui Pharma: ω-3 triglycerides (2%) medium/long-chain fat emulsion/amino acids (16)/glucose (30%) injection approved for market launch](https://longbridge.com/en/news/286885176.md)
*2026-05-19T09:19:05.000Z*
> Hengrui Pharma announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. has been approved by the National M

### [Seating in Financial Reports: Pricing Logic of the Top 50 Listed Pharmaceutical Companies in China](https://longbridge.com/en/news/286829407.md)
*2026-05-18T23:33:52.000Z*
> With the release of annual reports and first-quarter reports, the rankings of the top fifty pharmaceutical companies in 

### [Schroders PLC increased its holdings in Hengrui Pharma by 663,000 shares at an average price of approximately HKD 68.7 per share](https://longbridge.com/en/news/286766412.md)
*2026-05-18T11:57:05.000Z*
> According to the latest data from the Hong Kong Stock Exchange, on May 12, Schroders PLC increased its holdings in Hengr

### [The prosperity of the innovative drug industry continues, and the Hong Kong stock innovative drug ETF from Invesco encompasses the leading innovative drug stocks in Hong Kong. The off-market connection fund Class A 023597, Class C 023598](https://longbridge.com/en/news/286727578.md)
*2026-05-18T06:54:12.000Z*
> Hengrui Pharma has reached a cooperation agreement with BMS worth USD 15.2 billion, marking a new milestone in the globa

### [Hong Kong Stock Midday Review: The Hang Seng Index fell over 1% in the first half of the day, while chip stocks performed well against the trend](https://longbridge.com/en/news/286711749.md)
*2026-05-18T04:08:11.000Z*
> After falling for two consecutive days, the Hang Seng Index opened more than 100 points lower in the morning session, th

### [CNY 103.2 billion! China's innovative drugs have made a big deal again](https://longbridge.com/en/news/286495390.md)
*2026-05-15T02:03:04.000Z*
> Hengrui Pharma has reached a global BD deal with Bristol Myers Squibb (BMS) with a potential total amount of up to $15.2

### [Hengrui Pharma's clinical trial for the treatment of atopic dermatitis has been approved by the drug regulatory authority](https://longbridge.com/en/news/286486529.md)
*2026-05-15T00:42:00.000Z*
> Hengrui Pharma has received approval from the drug regulatory authority to conduct clinical trials for RSS0393 latex, ai

### [Zhitong Hong Kong Stock Connect Proportion Change Statistics | May 15](https://longbridge.com/en/news/286485560.md)
*2026-05-15T00:37:02.000Z*
> According to the data on May 14, 2026, the Hong Kong Stock Connect shareholding ratios of SICC, NSING TECH, and Hengrui 

### [Patent pool, second entry into China](https://longbridge.com/en/news/286665681.md)
*2026-05-14T15:59:44.000Z*
> Jiangsu Hengrui Pharma and Bristol Myers Squibb signed a strategic cooperation and licensing agreement to advance 13 ear